A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis

Area of Science:

• Oncology
• Genetics
• Epigenetics

Background:

• Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors, often fatal, with a majority harboring the H3K27M mutation.
• The H3K27M mutation impacts the function of enhancer of zeste homolog 2 (EZH2), a key enzyme in epigenetic regulation.
• The precise role of EZH2 in DMG pathogenesis remains largely undetermined.

Purpose of the Study:

• To investigate the function of EZH2 in diffuse midline glioma (DMG) development and progression.
• To elucidate the molecular mechanisms underlying EZH2's role in DMG pathogenesis using mouse models.
• To evaluate the therapeutic potential of EZH2 inhibition in DMG.

Main Methods:

• Utilized Ezh2 loss- and gain-of-function mouse models for H3WT DMG.
• Performed transcriptomic analysis to identify molecular pathways affected by Ezh2 modulation.
• Administered the EZH2 inhibitor Tazemetostat to H3K27M DMG tumor-bearing mice for in vivo assessment.

Main Results:

• Ezh2 ablation promoted cell proliferation and increased tumor grade in mouse models.
• Ezh2 gain-of-function mutations reduced tumor incidence and prolonged tumor latency.
• Transcriptomic analysis revealed Ezh2 deletion upregulated inflammatory and immunoproteasome genes, while gain-of-function enriched oxidative phosphorylation pathways.
• Pharmacological inhibition of EZH2 in neural progenitor cells increased proliferation, supporting its tumor-suppressive role.
• In vivo EZH2 inhibition with Tazemetostat did not significantly impact DMG tumor proliferation or survival.

Conclusions:

• EZH2 exhibits a tumor suppressor function in diffuse midline gliomas (DMG).
• The findings suggest caution is warranted regarding the clinical translation of EZH2 inhibitors for DMG treatment.
• Further research is needed to understand the complex role of EZH2 in DMG and identify effective therapeutic strategies.